ANALYSIS: Unravelling Japan’s Biosimilar Opportunities
This article was originally published in PharmAsia News
Executive Summary
MP Advisors sees a cumulative biosimilars opportunity of around JPY400 billion ($3.31 billion) in Japan over the next five years as some big-selling biologics come off local patent. But the next few years will provide further clarity on the value of different strategies for complex monoclonal antibody (mAb) biosimilar penetration in the country.